Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,260.00
Bid: 1,259.00
Ask: 1,262.00
Change: -8.00 (-0.63%)
Spread: 3.00 (0.238%)
Open: 1,255.00
High: 1,262.00
Low: 1,244.00
Prev. Close: 1,268.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

1 Feb 2022 09:23

RNS Number : 3008A
Indivior PLC
01 February 2022
 

 

 

 

Indivior to Announce FY 2021 Results and Host a Presentation on February 16th

Slough, UK, and Richmond, VA, February 1, 2022 - Indivior PLC (LON: INDV) today announced that it will release its FY 2021 results on February 16th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on February 16th.

Access to the Live Webcast Presentation

The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins.

The webcast link is: https://edge.media-server.com/mmc/p/8tao6fad

Participants may access the presentation telephonically:

· US participants 1-646-741-3167

· International participants +44 (0) 2071-928338

 

Please reference confirmation ID 8268632. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOREANAFEAEAEEA
Date   Source Headline
30th Dec 202212:29 pmRNSHolding(s) in Company
30th Dec 202212:28 pmRNSHolding(s) in Company
30th Dec 202212:25 pmRNSHolding(s) in Company
30th Dec 20227:00 amRNSTransaction in Own Shares
29th Dec 20223:38 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSTransaction in Own Shares
28th Dec 20228:59 amRNSHolding(s) in Company
28th Dec 20227:00 amRNSTransaction in Own Shares
23rd Dec 20227:00 amRNSTransaction in Own Shares
22nd Dec 20227:00 amRNSTransaction in Own Shares
21st Dec 20222:11 pmRNSHolding(s) in Company
21st Dec 20229:34 amRNSHolding(s) in Company
21st Dec 20227:00 amRNSTransaction in Own Shares
20th Dec 202210:15 amRNSBlock Listing of Shares
20th Dec 20227:00 amRNSTransaction in Own Shares
19th Dec 20227:00 amRNSTransaction in Own Shares
16th Dec 202211:14 amRNSHolding(s) in Company
16th Dec 202210:54 amRNSHolding(s) in Company
16th Dec 20227:00 amRNSTransaction in Own Shares
15th Dec 20222:08 pmRNSHolding(s) in Company
15th Dec 20229:08 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSTransaction in Own Shares
14th Dec 20227:00 amRNSTransaction in Own Shares
13th Dec 20227:00 amRNSTransaction in Own Shares
12th Dec 20227:00 amRNSTransaction in Own Shares
9th Dec 20221:04 pmRNSHolding(s) in Company
9th Dec 20227:00 amRNSTransaction in Own Shares
8th Dec 20227:00 amRNSTransaction in Own Shares
7th Dec 20227:00 amRNSIndivior Dec. 7 Capital Markets Day Highlights
7th Dec 20227:00 amRNSTransaction in Own Shares
6th Dec 20227:00 amRNSTransaction in Own Shares
5th Dec 20224:12 pmRNSHolding(s) in Company
5th Dec 20222:05 pmRNSSharesave Grant
5th Dec 20227:00 amRNSTransaction in Own Shares
2nd Dec 202212:27 pmRNSHolding(s) in Company
2nd Dec 20227:00 amRNSTransaction in Own Shares
1st Dec 20229:25 amRNSTotal Voting Rights
1st Dec 20227:00 amRNSTransaction in Own Shares
30th Nov 20223:32 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTransaction in Own Shares
29th Nov 20227:00 amRNSTransaction in Own Shares
28th Nov 202212:05 pmRNSHolding(s) in Company
28th Nov 20227:00 amRNSTransaction in Own Shares
25th Nov 20227:00 amRNSTransaction in Own Shares
24th Nov 20227:00 amRNSTransaction in Own Shares
23rd Nov 20224:25 pmRNSHolding(s) in Company
23rd Nov 20227:00 amRNSTransaction in Own Shares
22nd Nov 20222:36 pmRNSHolding(s) in Company
22nd Nov 20222:32 pmRNSHolding(s) in Company
22nd Nov 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.